With such substantial overlap between BRAF mutations and PD-L1 expression, our combined findings would support consideration of a clinical trial using BRAF/MEK inhibitors in combination with immune checkpoint inhibitors in craniopharyngioma patients with refractory or residual disease and in the neoadjuvant setting prior to radiation therapy. The gene discussed is MAP2K7; the disease is craniopharyngioma.